Bactrim + Macrobid

Bactrim + Macrobid in this context refers to a Phase 4 clinical trial regimen led by the University of Miami to evaluate the efficacy of prophylactic antibiotics in preventing urinary tract infections (UTIs) following outpatient urethral bulking procedures for stress urinary incontinence. Bactrim is a combination of sulfamethoxazole (a sulfonamide that inhibits dihydropteroate synthase) and trimethoprim (which inhibits dihydrofolate reductase), together blocking bacterial folic acid synthesis. Macrobid is a specific formulation of nitrofurantoin, a nitrofuran antibiotic that is reduced by bacterial flavoproteins to reactive intermediates that damage bacterial DNA, RNA, and proteins. In the study, Bactrim is the primary prophylactic agent, with Macrobid serving as the alternative for patients with sulfonamide allergies.

Other names

trimethoprim/sulfamethoxazolenitrofurantoinTMP-SMXnitrofurantoin monohydrate/macrocrystals